RXRX Q4 2025 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+687.8% YoY

Gross Profit

$9M24.4% margin

Operating Income

-$108M-304.8% margin

Net Income

-$108M-304.2% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+586.7%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$47M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$343M

Stockholders' Equity

$1.1B

Cash & Equivalents

$743M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$5M	+687.8%
Gross Profit	$9M	-$8M	+204.6%
Operating Income	-$108M	-$184M	+41.0%
Net Income	-$108M	-$179M	+39.6%

Revenue Segments

License and Service

$35M99%

Grant

$186,0001%

Geographic Segments

UNITED STATES

$17M100%